These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3332914)

  • 41. Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia.
    Simpson GM; Yadalam KG; Stephanos MJ
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):49S-51S. PubMed ID: 2906069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiparkinsonian activity of a single oral dose of PHNO.
    Grandas F; Quinn N; Critchley P; Rohan A; Marsden CD; Stahl SM
    Mov Disord; 1987; 2(1):47-51. PubMed ID: 2904120
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Double-blind trial of pergolide for Parkinson's disease.
    Diamond SG; Markham CH; Treciokas LJ
    Neurology; 1985 Mar; 35(3):291-5. PubMed ID: 3883232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Cinarizine and Parkinson's disease. Double-blind placebo-controlled study].
    Martí Massó JF
    Neurologia; 1986; 1(2):55-7. PubMed ID: 3079110
    [No Abstract]   [Full Text] [Related]  

  • 45. Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa.
    Leeman AL; O'Neill CJ; Nicholson PW; Deshmukh AA; Denham MJ; Royston JP; Dobbs RJ; Dobbs SM
    Br J Clin Pharmacol; 1987 Nov; 24(5):637-43. PubMed ID: 3325092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Depression treatment in Parkinson's disease.
    Driver PS
    DICP; 1991 Feb; 25(2):137-8. PubMed ID: 2058186
    [No Abstract]   [Full Text] [Related]  

  • 47. Elantrine in the treatment of parkinsonism.
    Blonsky ER
    Neurol Neurocir Psiquiatr; 1976; 17(4):231-8. PubMed ID: 798127
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1985; 8(3):260-5. PubMed ID: 3899352
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aggravation of Parkinson's disease by cinnarizine.
    Martí Massó JF; Obeso JA; Carrera N; Martínez-Lage JM
    J Neurol Neurosurg Psychiatry; 1987 Jun; 50(6):804-5. PubMed ID: 3302112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. UK Bromocriptine Research Group.
    J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):77-82. PubMed ID: 2651567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline).
    Agnoli A; Ruggieri S; Denaro A; Bruno G
    Neuropsychobiology; 1982; 8(6):289-96. PubMed ID: 7162583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Action of piribedil in Parkinson's disease: I.V. test and oral treatment.
    Emile J; Chanelet J; Truelle JL; Bastard J
    Adv Neurol; 1975; 9():409-13. PubMed ID: 1096577
    [No Abstract]   [Full Text] [Related]  

  • 53. Dynorphin agonist therapy of Parkinson's disease.
    Giuffra M; Mouradian MM; Davis TL; Ownby J; Chase TN
    Clin Neuropharmacol; 1993 Oct; 16(5):444-7. PubMed ID: 8106151
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlates of memory in Parkinson's disease.
    Riklan M; Reynolds CM; Stellar S
    J Nerv Ment Dis; 1989 Apr; 177(4):237-40. PubMed ID: 2703829
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Therapeutic effects of Nicholin (CDP-choline): Parkinson's syndrome.--a double-blind study].
    Tsubaki T; Kase M; Ando K; Manaka N; Sato Y
    Nihon Rinsho; 1974 Nov; 32(11):3435-50. PubMed ID: 4616105
    [No Abstract]   [Full Text] [Related]  

  • 56. Does papaverine interact with levodopa in Parkinson's disease?
    Montastruc JL; Rascol O; Belin J; Ane M; Rascol A
    Ann Neurol; 1987 Oct; 22(4):558-9. PubMed ID: 3324949
    [No Abstract]   [Full Text] [Related]  

  • 57. Behavioral effects of carbidopa/levodopa in hyperactive boys.
    Langer DH; Rapoport JL; Brown GL; Ebert MH; Bunney WE
    J Am Acad Child Psychiatry; 1982 Jan; 21(1):10-8. PubMed ID: 7047618
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of an experimental anticholinergic drug, elantrine, in treating the tremor of parkinsonism.
    Rix A
    Adv Exp Med Biol; 1977; 90():277-81. PubMed ID: 337773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease.
    Tsui JK; Wolters EC; Peppard RF; Calne DB
    Neurology; 1989 Jun; 39(6):856-8. PubMed ID: 2725884
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Niacin improved rigidity and bradykinesia in a Parkinson's disease patient but also caused unacceptable nightmares and skin rash--a case report.
    Alisky JM
    Nutr Neurosci; 2005; 8(5-6):327-9. PubMed ID: 16669604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.